Tumor programmed death‐ligand 1 (PD‐L1) expression, tumor‐infiltrating lymphocytes (TILs), and tumor mutation burden (TMB), etc., are used as indicators of clinical efficacy for ICI‐based immunotherapy.14 This evidence concerns the gene CD274 and neoplasm.